Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) posted quarterly Accumulated Depreciation of $1.6 million for Q4 2025, up 14.35% year-over-year from $1.4 million in Q4 2024, and up 14.35% quarter-over-quarter from $1.4 million in Q4 2024.
Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Accumulated Depreciation history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 14.35% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (up 14.35% YoY), while the FY2025 annual figure was $1.6 million, up 14.35% from the prior year.
- Accumulated Depreciation for Q4 2025 stood at $1.6 million, up from $1.4 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $1.6 million in Q4 2023, with the low at $53000.0 in Q4 2021.
- The 5-year median for Accumulated Depreciation is $1.4 million (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Depreciation soared 918.87% in 2022, then declined 16.52% in 2024.
- Amylyx Pharmaceuticals' Accumulated Depreciation stood at $53000.0 in 2021, then jumped by 918.87% to $540000.0 in 2022, then jumped by 201.48% to $1.6 million in 2023, then retreated by 16.52% to $1.4 million in 2024, then increased by 14.35% to $1.6 million in 2025.
- Business Quant data shows AMLX's Accumulated Depreciation at $1.6 million in Q4 2025, $1.4 million in Q4 2024, and $1.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.33 Bn | 4.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Dec 31, 2022 | 540,000.00 |
| Dec 31, 2021 | 53,000.00 |